RHY
Too good to be true... and I have already profited from it!
And coming originally from CSIRO, this is too good and IS true. However, if the current bigger research shows otherwise, then you can kiss your investment goodbye! CSIRO is not private and is also not known for shonky research!
https://rhy.irmau.com/site/PDF/59ea7425-7146-4325-adf7-b98566a3ef10/InvestorPresentationDecember2020
posted by Club Mulgoa @ 3:02 PM
1 Comments:
Based on what is already known from preliminary studies (early on by CSIRO), the ColoStat blood test has higher specificity and sensitivity than faecal occult blood test. Also only 40% of the packs sent out by government are used as it generates very poor compliance.
The test is around 50% of the price of faecal occult blood and so will be cheaper for a screening test too.
Patents are being collect for the biomarkers, and the most important market, the USA, has granted them for bowel cancer.
If the current large scale study supports the above notions, then the share price should explode. CSIRO stands to take a 5% royalty on sales of ColoStat and it deserves that! RHY is my number one stock for 2021 but I have often failed to pick the most successful equity!
Post a Comment
<< Home